drugset / Trial / NCT06118047

Crisaborole Ointment for Skin Toxicity Induced by Cetuximab

NCT06118047

Phase 2 Unknown 33 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, single-arm, phase II clinical trial that will enroll metastatic colorectal cancer patients with Cetuximab-Related Skin Toxicity, who will receive crisaborole ointment twice daily.

Timeline

Start
2023-08-01
Primary completion
2024-12-31
Completion
2025-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Crisaborole Small molecule Topical
Background Cetuximab Monoclonal antibody